Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Clinical_Trials
|
| gptkbp:analysis |
survival analysis
|
| gptkbp:clinical_trial |
NCT03036098
|
| gptkbp:collaborator |
various research institutions
|
| gptkbp:collection |
clinical assessments
patient-reported outcomes |
| gptkbp:criteria |
adults with advanced NSCLC
previous immunotherapy |
| gptkbp:design |
randomized controlled trial
|
| gptkbp:events |
at least 2 years
|
| gptkbp:finale_date |
safety and tolerability
|
| gptkbp:focuses_on |
gptkb:Oncology
|
| gptkbp:future_prospects |
new treatment protocols
combination therapies long-term effects of treatment |
| https://www.w3.org/2000/01/rdf-schema#label |
The Check Mate 227 Trial
|
| gptkbp:impact |
lung cancer treatment guidelines
|
| gptkbp:is_compared_to |
nivolumab plus ipilimumab vs chemotherapy
|
| gptkbp:is_tested_for |
Phase 3
|
| gptkbp:location |
multiple countries
|
| gptkbp:outcomes_reported |
response rates
safety profile quality of life measures long-term survival rates |
| gptkbp:participants |
overall survival
progression-free survival |
| gptkbp:patient_population |
diverse demographics
|
| gptkbp:primary_use |
treatment
|
| gptkbp:publication |
peer-reviewed journals
|
| gptkbp:randomization_ratio |
1:1:1
|
| gptkbp:regulatory_compliance |
FDA approval for ipilimumab
FDA approval for nivolumab |
| gptkbp:related_products |
gptkb:ipilimumab
gptkb:nivolumab chemotherapy agents |
| gptkbp:research_focus |
PD-L1 expression
biomarkers for response tumor mutational burden |
| gptkbp:result |
gptkb:2021
|
| gptkbp:results_type |
interim results
|
| gptkbp:side_effect |
monitored throughout study
|
| gptkbp:sponsor |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:start_date |
gptkb:2017
|
| gptkbp:student_enrollment |
over 2000 patients
|
| gptkbp:treatment |
gptkb:ipilimumab
gptkb:nivolumab chemotherapy |
| gptkbp:vision |
open-label
|
| gptkbp:year |
gptkb:2020
|
| gptkbp:bfsParent |
gptkb:The_New_England_Journal_of_Medicine
|
| gptkbp:bfsLayer |
6
|